

## FINANCIAL TEAR SHEET

### Corporate Profile

We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our collaborators – a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine, and pain.

### Stock Performance

#### XENE (Common Stock)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$11.70</b>
<b>Change (%)</b>	<span style="color: green;">▲</span> 0.30 (2.63%)
<b>Volume</b>	48,802
<b>52 Week Low</b>	\$2.10
<b>Market Cap</b>	\$219,585,535
<b>Rolling EPS</b>	-1.60
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	19,261,889



Data as of 08/15/18 4:00 p.m. ET

# Recent Press Releases & Upcoming Events

August 7, 2018 - [Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update](#)

There are currently no events scheduled.

August 3, 2018 - [Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update](#)

July 12, 2018 - [Xenon Pharmaceuticals Announces At-The-Market Equity Offering](#)

## SEC Filings

Filing Date	Form
08/10/18	<a href="#"><u>SC 13G/A</u></a>
08/07/18	<a href="#"><u>10-Q</u></a>
08/07/18	<a href="#"><u>8-K</u></a>
08/07/18	<a href="#"><u>8-K</u></a>

## Corporate Governance

[Simon Pimstone, MBChB, Ph.D., FRCPC](#)

[Ian Mortimer, MBA, CPA, CMA](#)

[Ernesto Aycardi, M.D.](#)

[Robin Sherrington, Ph.D.](#)

[James Empfield, Ph.D.](#)

[Charles Cohen, PhD](#)

[Jodi Regts, BA, MBA](#)

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)